Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-positive gastric cancer, drawn from the whole corpus: 24 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
HER2 heterogeneity and loss after treatment make a single biopsy unreliable.
No HER2-directed therapy has yet improved cure rates in resectable disease.
Interstitial lung disease with trastuzumab deruxtecan needs early recognition.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
PFS 12.
OS 14.
A milestone in how this cancer is treated.
Confirmed durable responses to trastuzumab deruxtecan in a Western population after progression on trastuzumab.
Higher response rate and longer progression-free survival with pembrolizumab added to trastuzumab and chemotherapy, with benefit concentrated in PD-L1-positive tumours; accelerated approval in May 2021, later limited to PD-L1 combined positive score of 1 or more.